ATE275143T1 - Verbindungen - Google Patents

Verbindungen

Info

Publication number
ATE275143T1
ATE275143T1 AT00987916T AT00987916T ATE275143T1 AT E275143 T1 ATE275143 T1 AT E275143T1 AT 00987916 T AT00987916 T AT 00987916T AT 00987916 T AT00987916 T AT 00987916T AT E275143 T1 ATE275143 T1 AT E275143T1
Authority
AT
Austria
Prior art keywords
links
compounds
directed
general formula
present application
Prior art date
Application number
AT00987916T
Other languages
English (en)
Inventor
William Brown
Christopher Walpole
Niklas Plobeck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE275143T1 publication Critical patent/ATE275143T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Liquid Crystal (AREA)
  • Furan Compounds (AREA)
AT00987916T 1999-12-20 2000-12-15 Verbindungen ATE275143T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904674A SE9904674D0 (sv) 1999-12-20 1999-12-20 Novel compounds
PCT/SE2000/002562 WO2001046174A1 (en) 1999-12-20 2000-12-15 Novel compounds

Publications (1)

Publication Number Publication Date
ATE275143T1 true ATE275143T1 (de) 2004-09-15

Family

ID=20418210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00987916T ATE275143T1 (de) 1999-12-20 2000-12-15 Verbindungen

Country Status (31)

Country Link
US (2) US6680318B2 (de)
EP (1) EP1242410B1 (de)
JP (1) JP2003522741A (de)
KR (2) KR100769814B1 (de)
CN (1) CN1608064A (de)
AT (1) ATE275143T1 (de)
AU (1) AU780799B2 (de)
BG (1) BG65457B1 (de)
BR (1) BR0016591A (de)
CA (1) CA2395300A1 (de)
CZ (1) CZ20022124A3 (de)
DE (1) DE60013486T2 (de)
DK (1) DK1242410T3 (de)
EE (1) EE200200337A (de)
ES (1) ES2225289T3 (de)
HK (1) HK1048308B (de)
HU (1) HUP0300020A3 (de)
IL (2) IL150125A0 (de)
IS (1) IS2143B (de)
MX (1) MXPA02006063A (de)
NO (1) NO322432B1 (de)
NZ (1) NZ519986A (de)
PL (1) PL356780A1 (de)
PT (1) PT1242410E (de)
RU (1) RU2258703C2 (de)
SE (1) SE9904674D0 (de)
SI (1) SI1242410T1 (de)
SK (1) SK8832002A3 (de)
UA (1) UA71650C2 (de)
WO (1) WO2001046174A1 (de)
ZA (1) ZA200204255B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
CA2446326C (en) * 2001-05-18 2010-12-07 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
RU2314809C2 (ru) * 2001-10-29 2008-01-20 Маунт Кук Байосайенсиз, Инк. Способ лечения депрессии соединениями-агонистами дельта-рецепторов
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
EP1697307B1 (de) * 2003-12-12 2014-03-12 Eli Lilly & Company Antagonisten des opioidrezeptors
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
KR101234421B1 (ko) * 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도
US20080262229A1 (en) * 2005-02-28 2008-10-23 Astrazeneca Ab Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof
GB0606876D0 (en) * 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
AU2009249714A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Method of treating anxious major depressive disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH583713A5 (de) 1973-06-29 1977-01-14 Cermol Sa
DE2900810A1 (de) 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
ES2173883T3 (es) 1989-11-22 2002-11-01 Janssen Pharmaceutica Nv Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
FR2696744B1 (fr) 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
RU2133744C1 (ru) 1993-07-30 1999-07-27 Дельта Фармасьютикалз, Инк. Пиперазиновые соединения
JP3352184B2 (ja) 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
SE9504661D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US5693843A (en) * 1995-12-22 1997-12-02 E. I. Du Pont De Nemours And Company Process for hydrocyanation of diolefins and isomerization of nonconjugated 2 alkyl-3-monoalkenenitriles
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds

Also Published As

Publication number Publication date
US20030105110A1 (en) 2003-06-05
RU2258703C2 (ru) 2005-08-20
SE9904674D0 (sv) 1999-12-20
KR20070090050A (ko) 2007-09-04
EP1242410B1 (de) 2004-09-01
US20040138225A1 (en) 2004-07-15
ZA200204255B (en) 2003-08-28
US6680318B2 (en) 2004-01-20
DE60013486T2 (de) 2005-11-17
RU2002114343A (ru) 2004-01-10
HUP0300020A2 (en) 2003-05-28
WO2001046174A1 (en) 2001-06-28
JP2003522741A (ja) 2003-07-29
CZ20022124A3 (cs) 2002-11-13
AU780799B2 (en) 2005-04-21
KR100769814B1 (ko) 2007-10-23
IS2143B (is) 2006-09-15
SI1242410T1 (en) 2004-12-31
HUP0300020A3 (en) 2005-02-28
CA2395300A1 (en) 2001-06-28
KR20020062350A (ko) 2002-07-25
NO20022920L (no) 2002-07-22
IL150125A0 (en) 2002-12-01
PL356780A1 (en) 2004-07-12
NO322432B1 (no) 2006-10-02
SK8832002A3 (en) 2003-03-04
AU2418401A (en) 2001-07-03
MXPA02006063A (es) 2003-02-06
EP1242410A1 (de) 2002-09-25
EE200200337A (et) 2003-10-15
HK1048308A1 (en) 2003-03-28
IL150125A (en) 2006-08-20
BR0016591A (pt) 2002-09-10
DK1242410T3 (da) 2004-11-29
CN1608064A (zh) 2005-04-20
ES2225289T3 (es) 2005-03-16
UA71650C2 (uk) 2004-12-15
BG65457B1 (bg) 2008-08-29
NO20022920D0 (no) 2002-06-18
BG106805A (en) 2003-03-31
PT1242410E (pt) 2004-12-31
NZ519986A (en) 2004-06-25
IS6426A (is) 2002-06-18
HK1048308B (zh) 2005-04-08
DE60013486D1 (de) 2004-10-07

Similar Documents

Publication Publication Date Title
DE69907977D1 (de) Pyrrolobenzodiazepine
ATE299890T1 (de) Inhibitoren von gamma-secretase
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
SE0101387D0 (sv) Novel compounds
DE59709414D1 (de) Oxyiminopregnancarbolactone
ATE275143T1 (de) Verbindungen
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
AP2001002318A0 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NO20002440L (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
DE60121461D1 (de) Kondensierte pyridoindolderivate
SE9802208D0 (sv) Novel compounds
NO20002218D0 (no) Anvendelse av mirtazepin for behandling av søvnapne
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SE9903290D0 (sv) Novel compounds
SE0004101D0 (sv) New use
SE9802209D0 (sv) Novel compounds
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
TR200003084T2 (tr) Paroxetine askorbat
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
UY26102A1 (es) Derivados de 1-aminoetilindol, su preparación y su aplicación en terapéutica
SE9802207D0 (sv) Novel compounds
ES2148057A1 (es) Nuevo uso del diacepam como potenciador del efecto de los inhibidores pde 3
FI991138A0 (fi) Normobarisen hypoksian käyttö terapeuttisesti

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242410

Country of ref document: EP

REN Ceased due to non-payment of the annual fee